Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor

被引：0
|
作者：
Chica-Parrado, M. Rosario
Chica-Parrado, M. Rosario
Lin, Chang-Ching
Mahoney, Timothy
Mauer, Elizabeth
Hanker, Ariella
Arteaga, Carlos
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P5-02-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-02-02
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Treatment patterns and clinical outcomes in ER+/HER2-metastatic breast cancer in German real world settings
    Mitra, D.
    Kurosky, S.
    Kaye, J.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S141 - S141
  • [32] IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER +/HER2-metastatic breast cancer
    Cosci, C.
    Jamme, P.
    Kumar, V.
    Nadler, M. B.
    Rayson, D.
    Melvin, J.
    Rushton, M.
    Awan, A.
    Levasseur, N.
    Chia, S.
    Bedard, P.
    Hilton, J.
    Finn, S.
    Tu, W.
    Antras, J. F.
    Unger, T. J.
    Cescon, D.
    Seymour, L.
    Pearce, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S173 - S174
  • [33] Longitudinal, multimodal profiling of metastatic ER plus breast cancer on CDK4/6 inhibitor therapy
    Creason, Allison L.
    Egger, Julian
    Watson, Cameron
    Sivagnanam, Shamilene
    Lin, Jia-Ren
    Chin, Koei
    Sorger, Peter K.
    Coussens, Lisa M.
    Mitri, Zahi I.
    Gray, Joe W.
    Mills, Gordon B.
    Goecks, Jeremy
    CANCER RESEARCH, 2023, 83 (07)
  • [34] CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2-advanced breast cancer with impending or established visceral crisis
    Behrouzi, Roya
    Armstrong, Anne C.
    Howell, Sacha J.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (01) : 83 - 95
  • [35] CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
    Roya Behrouzi
    Anne C. Armstrong
    Sacha J. Howell
    Breast Cancer Research and Treatment, 2023, 202 : 83 - 95
  • [36] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [37] Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Moiso, Enrico
    Ferraro, Emanuela
    Cabel, Luc
    Safonov, Anton
    Ahmed, Mehnaj
    An, Julia Ah-Reum
    Jhaveri, Komal L.
    Norton, Larry
    Robson, Mark E.
    Modi, Shanu
    Chandarlapaty, Sarat
    Razavi, Pedram
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
    Chen, Anran
    Kim, Beom-Jun
    Mitra, Aparna
    Vollert, Craig T.
    Lei, Jonathan T.
    Fandino, Diana
    Anurag, Meenakshi
    Holt, Matthew V.
    Gou, Xuxu
    Pilcher, Jacob B.
    Goetz, Matthew P.
    Northfelt, Donald W.
    Hilsenbeck, Susan G.
    Marshall, C. Gary
    Hyer, Marc L.
    Papp, Robert
    Yin, Shou-Yun
    De Angelis, Carmine
    Schiff, Rachel
    Fuqua, Suzanne A. W.
    Ma, Cynthia X.
    Foulds, Charles E.
    Ellis, Matthew J.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1494 - 1510
  • [39] Analyzing the changes in the HR+/HER2-metastatic breast cancer (mBC) landscape since the arrival of CDK4/6 inhibitors with machine learning and visual analytics
    Meade, D.
    Alford, S. Hensley
    Mahatma, S.
    Malangone-Monaco, E.
    Boulanger, L.
    Tkacz, J.
    Turner, S. J.
    Chen, S.
    Manson, S.
    Mejia, S.
    Buleje, I.
    Madan, P.
    Kim, G.
    Fowler, R.
    Basar, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [40] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
    Galardi, F.
    Biagioni, C.
    De Luca, F.
    Curigliano, G.
    Minisini, A. M.
    Bonechi, M.
    Moretti, E.
    Risi, E.
    Migliaccio, I.
    McCartney, A.
    Benelli, M.
    Romagnoli, D.
    Conti, V.
    Biganzoli, L.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S18 - S18
12345